The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
This type of tracking helps a practice understand how radiologists interact with AI, whether they're appropriately rejecting incorrect results, and if the technology is improving detection of important findings.
Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's FDA 510(k)-pending photon-counting CT scanner.
Intravascular lithotripsy is expected to see even wider adoption when lower-profile catheters are introduced and device costs start to drop, explained Samin Sharma, MD.
As of January 2026, there will only be two CPT category 1 payment codes for newer AI, despite there being hundreds of FDA-cleared medical imaging algorithms.
Herbert D. Aronow, MD, reviewed the many ways the reimbursement landscape is changing thanks to new Medicare policies. “This is a really exciting time in the renal denervation space," he said.
A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.
A growing number of private insurers are now covering these advanced technologies. Roosha Parikh, MD, told Cardiovascular Business that the hard work of SCCT and other groups has helped make this happen.
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
The U.S. Food and Drug Administration has green-lit new updates that improve microvascular flow, AI-assisted harmonic imaging and elastography, which Canon will showcase at RSNA 2025.
